Coller et al., “Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation,” J. Biol. Chem., 268(28):20741-20743 (1993). |
Couder, et al., “Synthesis and Biological Activities of ψ(CH2NH) Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin,” Internat. J. Peptide & Protein Res., 41(2):181-183 (1993). |
DalPozzo, et al. “H-Gly-Hisψ(NHCO)Lys-OH, Partially Modified Retro-Inverso Analogue of the Growth Factor Glycyl-L-histidyl-l-lysine with Enhanced Enzymatic Stability,” Int. J. Peptide Protein Res., 561-566 (1993). |
Hupp, et al., “Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases,” Cold Spring Harbor Symposia on Quantitative Biology, vol. LIX, pp. 195-205 (1994). |
Hupp, et al., “Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53,” Cell, 83:237-245 (1995). |
Shaw et al., “Rgulation of specific DNA Binding by p53: Evidence for a Role for o-Glycosylation and Charged Residues at the Carboxy-terminus,” Oncogene, 12:921-930 (1996). |
Takenaka, et al., “Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases,” J. Biol. Chem., 270(10):5405-5411 (1995). |
Tanigaki, et al., “The Peptide Binding Specificity of HLA-B27 Subtypes,” Immunogenetics, 40:192-198 (1994). |
Wade-Evans, et al., “Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53” (1985) EMBO J., 4:699-706. |
Finlay, et al., “The p53 Proto-Oncogene Can Act As A Suppressor of Transformation” (1989) Cell, 57:1083-1093. |
Soussi, et al., “Structural Aspects of the p53 Protein in Relation to Gene Evolution” (1990) Oncogene, 5:945-952. |
Hupp, et al., “Regulation of the Specific DNA Binding Function of p53” (1992), Cell, 71:875-886. |
Hruby, Victor J., “Conformational and Topographical Considerations in the Design of Biologically Active Peptides” (1993) Biopolymers, 33:1073-1082. |
Powell, et al., “Peptide Stability in Drug Development. II. Effect of Single Amino Acid Substitution and Glycosylation on Peptide Reactivity in Human Serum” (1993) Pharma. Res., 10:1268-1273. |
Hupp, et al., “Activation of the Cryptic DNA Binding Function of Mutant Forms of p53” (1993) Nucleic Acids Res., 21:3167-3174. |
Fujiwara, et al., “A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis” (1993) Cancer Res., 53:4129-4133. |
Halazonetis, et al., “Wild-Type p53 Adopts a ‘Mutant’-Like Conformation When Bound to DNA” (1993) EMBO J., 12:1021-1028. |
Halazonetis, et al., “Conformational Shifts Propagate From the Oligomerization Domain of p53 to Its Tetrameric DNA Finding Domain and Restore DNA Binding to Select p53 Mutants” (1993) EMBO J., 12:5057-5064. |
Bugg, et al., “Drugs by Design” (1993) Sci. Am., 269:92-98. |
Hupp, et al., “Allosteric Activation of Latent p53 Tetramers” (1994) Current Biology, 4:865-875. |
Friend, S., “p53: A Glimpse at the Puppet Behind the Shadow Play” (1994) Science, 265:334-335. |
Cho, et al., “Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations” (1994) Science, 265:346-355. |
Clore, et al., “High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR” (1994) Science, 265:386-391. |
Speir, et al., “Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis” (1994) Science, 265:391-394. |
Cox, et al., “Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced Upon DNA Damage in Somatic Cells” (1994) Oncogene, 9:2951-2959. |
Brady, et al., “Reflections on a Peptide” (1994) Nature, 368:692-693. |
Jameson, et al., “A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis” (1994) Nature, 368:744-746. |
Moore, Graham J., “Designing Peptide Mimetics” (1994) Trends Pharmacol. Sci., 15:124-129. |
Dean, Phillip M., “Recent Advances in Drug Design Methods: Where Will They Lead?” (1994) BioEssays, 16:683-687. |
Hupp et al, “Small peptides activate the latent sequence-specific DNA binding function of p53” Cell, vol. 83, pp. 237-245. |
Tanigaki et al, “The peptide binding specificity of HLA B27 subtypes”, Immunogenetics, vol. 40, pp. 192-198. |
Hupp et al. “Allosteric activation of latent p53 tetramers”, Current Biology, vol. 4, No. 10, pp. 865-875. |
Powell et al, “Peptide stability in drug development. II. effect of single amino acid substitution and glysosylation on peptide reactivity in human serum” Parmaceutical Research, vol. 10, No. 9, pp. 1268-1273. |
Couder et al, “Synthesis and biological activities of (Ch2NH) pseudopeptide analogues of the C-terminal hexapeptide of neurotensin”, Int. J. Peptide Protein Res., vol. 41, pp. 181-184. |
Dalpozzo et al, “H-Gly-His(NHCO)Lys-OH, partially modifield retro-inverso analogue of the growth factor glycyl-L-histidyl-L-lysine with enhanced enzymatic stability”, Int. J. Peptide Protein Res., vol. 41, pp. 561-566 |
Stryer. Biochemistry second edition, pp. 13-17.* |